Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy

Jan Novak, Kazuo Takahashi, Hitoshi Suzuki, Colin Reily, Tyler Stewart, Hiroyuki Ueda, Koshi Yamada, Zina Moldoveanu, M. Colleen Hastings, Robert J. Wyatt, Jiri Mestecky, Milan Raska, Bruce A. Julian, Matthew B. Renfrow

研究成果: Chapter

2 引用 (Scopus)

抄録

IgA nephropathy (IgAN), a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (Gd-IgA1; autoantigen) and anti-glycan autoantibodies deposit in the glomeruli and induce renal injury. Serum IgA1 has three to six clustered O-glycans, some of which may be deficient in galactose and thus expose terminal or sialylated N-acetylgalactosamine. Patients with IgAN usually have elevated serum levels of Gd-IgA1. The mechanisms involved in production of Gd-IgA1 are not fully understood. Using IgA1-producing cell lines, we have analyzed the heterogeneity of IgA1 O-glycosylation and the corresponding biosynthetic pathways. IgA1 secreted by cells from IgAN patients vs. healthy controls had more galactose-deficient sites and overall more O-glycans. These changes were associated with differential expression/ activity of key glycosyltransferases in cells from patients with IgAN vs. controls, elevated for an initiating enzyme N-acetylgalactosaminyl (GalNAc)- transferase 14 and for GalNAc-specific sialyltransferase (ST6GalNAc-II) and, conversely, decreased for the galactosyltransferase (C1GalT1) and C1GalT1- associated chaperone Cosmc. Involvement of the key enzymes in the production of Gd-IgA1 was confirmed by siRNA knockdown and biochemical approaches. Moreover, expression of these enzymes is affected by some cytokines that further enhance the enzyme imbalance to increase Gd-IgA1 production. In summary, the production of Gd-IgA1, the key autoantigen in IgAN, by IgA1- secreting cells results from dysregulation of key glycosyltransferases and is augmented by certain cytokines. These findings provide insight into possible approaches for future disease-specific therapy.

元の言語English
ホスト出版物のタイトルPathogenesis and Treatment in IgA Nephropathy
ホスト出版物のサブタイトルAn International Comparison
出版者Springer Japan
ページ53-68
ページ数16
ISBN(電子版)9784431555889
ISBN(印刷物)9784431555872
DOI
出版物ステータスPublished - 10-03-2016

Fingerprint

Glycosylation
Immunoglobulin A
Polysaccharides
Galactose
Glycosyltransferases
Autoantigens
Enzymes
Cytokines
Galactosyltransferases
Acetylgalactosamine
Biosynthetic Pathways
Antigen-Antibody Complex
Serum
Autoantibodies
Small Interfering RNA
Autoimmune Diseases
Chronic Kidney Failure

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Novak, J., Takahashi, K., Suzuki, H., Reily, C., Stewart, T., Ueda, H., ... Renfrow, M. B. (2016). Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy. : Pathogenesis and Treatment in IgA Nephropathy: An International Comparison (pp. 53-68). Springer Japan. https://doi.org/10.1007/978-4-431-55588-9_4
Novak, Jan ; Takahashi, Kazuo ; Suzuki, Hitoshi ; Reily, Colin ; Stewart, Tyler ; Ueda, Hiroyuki ; Yamada, Koshi ; Moldoveanu, Zina ; Hastings, M. Colleen ; Wyatt, Robert J. ; Mestecky, Jiri ; Raska, Milan ; Julian, Bruce A. ; Renfrow, Matthew B. / Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy. Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, 2016. pp. 53-68
@inbook{1399d90a99d74471879b6e7d9e119f2c,
title = "Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy",
abstract = "IgA nephropathy (IgAN), a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (Gd-IgA1; autoantigen) and anti-glycan autoantibodies deposit in the glomeruli and induce renal injury. Serum IgA1 has three to six clustered O-glycans, some of which may be deficient in galactose and thus expose terminal or sialylated N-acetylgalactosamine. Patients with IgAN usually have elevated serum levels of Gd-IgA1. The mechanisms involved in production of Gd-IgA1 are not fully understood. Using IgA1-producing cell lines, we have analyzed the heterogeneity of IgA1 O-glycosylation and the corresponding biosynthetic pathways. IgA1 secreted by cells from IgAN patients vs. healthy controls had more galactose-deficient sites and overall more O-glycans. These changes were associated with differential expression/ activity of key glycosyltransferases in cells from patients with IgAN vs. controls, elevated for an initiating enzyme N-acetylgalactosaminyl (GalNAc)- transferase 14 and for GalNAc-specific sialyltransferase (ST6GalNAc-II) and, conversely, decreased for the galactosyltransferase (C1GalT1) and C1GalT1- associated chaperone Cosmc. Involvement of the key enzymes in the production of Gd-IgA1 was confirmed by siRNA knockdown and biochemical approaches. Moreover, expression of these enzymes is affected by some cytokines that further enhance the enzyme imbalance to increase Gd-IgA1 production. In summary, the production of Gd-IgA1, the key autoantigen in IgAN, by IgA1- secreting cells results from dysregulation of key glycosyltransferases and is augmented by certain cytokines. These findings provide insight into possible approaches for future disease-specific therapy.",
author = "Jan Novak and Kazuo Takahashi and Hitoshi Suzuki and Colin Reily and Tyler Stewart and Hiroyuki Ueda and Koshi Yamada and Zina Moldoveanu and Hastings, {M. Colleen} and Wyatt, {Robert J.} and Jiri Mestecky and Milan Raska and Julian, {Bruce A.} and Renfrow, {Matthew B.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1007/978-4-431-55588-9_4",
language = "English",
isbn = "9784431555872",
pages = "53--68",
booktitle = "Pathogenesis and Treatment in IgA Nephropathy",
publisher = "Springer Japan",
address = "Japan",

}

Novak, J, Takahashi, K, Suzuki, H, Reily, C, Stewart, T, Ueda, H, Yamada, K, Moldoveanu, Z, Hastings, MC, Wyatt, RJ, Mestecky, J, Raska, M, Julian, BA & Renfrow, MB 2016, Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy. : Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, pp. 53-68. https://doi.org/10.1007/978-4-431-55588-9_4

Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy. / Novak, Jan; Takahashi, Kazuo; Suzuki, Hitoshi; Reily, Colin; Stewart, Tyler; Ueda, Hiroyuki; Yamada, Koshi; Moldoveanu, Zina; Hastings, M. Colleen; Wyatt, Robert J.; Mestecky, Jiri; Raska, Milan; Julian, Bruce A.; Renfrow, Matthew B.

Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, 2016. p. 53-68.

研究成果: Chapter

TY - CHAP

T1 - Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy

AU - Novak, Jan

AU - Takahashi, Kazuo

AU - Suzuki, Hitoshi

AU - Reily, Colin

AU - Stewart, Tyler

AU - Ueda, Hiroyuki

AU - Yamada, Koshi

AU - Moldoveanu, Zina

AU - Hastings, M. Colleen

AU - Wyatt, Robert J.

AU - Mestecky, Jiri

AU - Raska, Milan

AU - Julian, Bruce A.

AU - Renfrow, Matthew B.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - IgA nephropathy (IgAN), a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (Gd-IgA1; autoantigen) and anti-glycan autoantibodies deposit in the glomeruli and induce renal injury. Serum IgA1 has three to six clustered O-glycans, some of which may be deficient in galactose and thus expose terminal or sialylated N-acetylgalactosamine. Patients with IgAN usually have elevated serum levels of Gd-IgA1. The mechanisms involved in production of Gd-IgA1 are not fully understood. Using IgA1-producing cell lines, we have analyzed the heterogeneity of IgA1 O-glycosylation and the corresponding biosynthetic pathways. IgA1 secreted by cells from IgAN patients vs. healthy controls had more galactose-deficient sites and overall more O-glycans. These changes were associated with differential expression/ activity of key glycosyltransferases in cells from patients with IgAN vs. controls, elevated for an initiating enzyme N-acetylgalactosaminyl (GalNAc)- transferase 14 and for GalNAc-specific sialyltransferase (ST6GalNAc-II) and, conversely, decreased for the galactosyltransferase (C1GalT1) and C1GalT1- associated chaperone Cosmc. Involvement of the key enzymes in the production of Gd-IgA1 was confirmed by siRNA knockdown and biochemical approaches. Moreover, expression of these enzymes is affected by some cytokines that further enhance the enzyme imbalance to increase Gd-IgA1 production. In summary, the production of Gd-IgA1, the key autoantigen in IgAN, by IgA1- secreting cells results from dysregulation of key glycosyltransferases and is augmented by certain cytokines. These findings provide insight into possible approaches for future disease-specific therapy.

AB - IgA nephropathy (IgAN), a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (Gd-IgA1; autoantigen) and anti-glycan autoantibodies deposit in the glomeruli and induce renal injury. Serum IgA1 has three to six clustered O-glycans, some of which may be deficient in galactose and thus expose terminal or sialylated N-acetylgalactosamine. Patients with IgAN usually have elevated serum levels of Gd-IgA1. The mechanisms involved in production of Gd-IgA1 are not fully understood. Using IgA1-producing cell lines, we have analyzed the heterogeneity of IgA1 O-glycosylation and the corresponding biosynthetic pathways. IgA1 secreted by cells from IgAN patients vs. healthy controls had more galactose-deficient sites and overall more O-glycans. These changes were associated with differential expression/ activity of key glycosyltransferases in cells from patients with IgAN vs. controls, elevated for an initiating enzyme N-acetylgalactosaminyl (GalNAc)- transferase 14 and for GalNAc-specific sialyltransferase (ST6GalNAc-II) and, conversely, decreased for the galactosyltransferase (C1GalT1) and C1GalT1- associated chaperone Cosmc. Involvement of the key enzymes in the production of Gd-IgA1 was confirmed by siRNA knockdown and biochemical approaches. Moreover, expression of these enzymes is affected by some cytokines that further enhance the enzyme imbalance to increase Gd-IgA1 production. In summary, the production of Gd-IgA1, the key autoantigen in IgAN, by IgA1- secreting cells results from dysregulation of key glycosyltransferases and is augmented by certain cytokines. These findings provide insight into possible approaches for future disease-specific therapy.

UR - http://www.scopus.com/inward/record.url?scp=85028529854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028529854&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55588-9_4

DO - 10.1007/978-4-431-55588-9_4

M3 - Chapter

AN - SCOPUS:85028529854

SN - 9784431555872

SP - 53

EP - 68

BT - Pathogenesis and Treatment in IgA Nephropathy

PB - Springer Japan

ER -

Novak J, Takahashi K, Suzuki H, Reily C, Stewart T, Ueda H その他. Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy. : Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan. 2016. p. 53-68 https://doi.org/10.1007/978-4-431-55588-9_4